T3 Phar­ma­ceu­ti­cals com­pletes sec­ond fi­nanc­ing round; Mod­er­na, Har­vard Med­ical School to tack­le im­muno­log­i­cal dis­eases

→ Uni­ver­si­ty of Basel, Switzer­land spin­out T3 Phar­ma­ceu­ti­cals has raised 12 mil­lion CHF at the close of its sec­ond fi­nanc­ing round. Cur­rent in­vestors were joined by Boehringer In­gel­heim Ven­ture Fund and Ref­er­ence Cap­i­tal SA. The round will help pro­pel the can­cer-fo­cused com­pa­ny’s lead prod­uct, T3P-Y058-739, in­to clin­i­cal test­ing, which is ex­pect­ed to be­gin in the mid­dle of 2020.

In ad­di­tion, the com­pa­ny wel­comed aboard Claire Bar­ton as CMO af­ter hav­ing been with the com­pa­ny as a con­sul­tant for the past 18 months. Her pre­vi­ous stints in­clude roles at Glax­oW­ell­come, Lil­ly and Roche.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER